Two Disease-State Suppliers With Different Strengths
Researchers evaluating OrganaBio and Sanguine Biosciences are usually asking the same underlying question: which supplier can get me the patient-derived cells I need, with the annotation I need, in a format that works for my protocol?
The honest answer depends on what you’re doing. This comparison covers the meaningful differences between the two programs — indication breadth, clinical annotation depth, GMP capability, and how each supplier’s business model shapes what you actually receive.
Indication Breadth
Sanguine’s disease-state portfolio covers 150+ conditions across autoimmune, inflammatory, metabolic, neurological, and oncological indications. The breadth is genuine and is the strongest argument for Sanguine when a program needs rare indications or highly specific disease subtype access.
OrganaBio’s disease-state portfolio covers 24 indications, focused on the autoimmune and oncology indications with the highest research volume: SLE, rheumatoid arthritis, type 1 diabetes, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, NHL, AML, multiple sclerosis, and others. The narrower footprint reflects a deliberate focus: OrganaBio characterizes its donors more deeply and maintains tighter processing standards rather than expanding to the long tail of rare indications.
When Sanguine wins this comparison: programs needing indications outside OrganaBio’s 24-indication portfolio — rare autoimmune conditions, neurological disorders, metabolic disease subtypes — where Sanguine’s breadth is the only option.
When OrganaBio wins this comparison: programs in the core autoimmune and oncology space where annotation depth and integration with GMP infrastructure matter more than indication breadth.
Clinical Annotation
Sanguine’s annotation model relies on a decentralized patient donor network — donors recruited primarily through digital channels and community partnerships, with clinical data collected via standardized questionnaires at the time of enrollment. The breadth of the donor network enables the large indication portfolio; the tradeoff is that annotation depth depends on what donors self-report and what’s in their available medical record.
OrganaBio’s annotation model for disease-state donors integrates clinical partnership with collection infrastructure. Key annotation fields — disease activity scores, medication history, confirmation of diagnosis by clinical criteria — are gathered through structured clinical data collection protocols rather than patient self-report alone.
For basic research and initial screening applications, Sanguine’s annotation is sufficient. For translational work where disease activity at time of collection, treatment status, and clinical subtype need to be confirmed against defined criteria, annotation depth matters and the collection model affects what’s available.
GMP Manufacturing Capability
This is the clearest structural distinction between the two companies. Sanguine’s business model is built around research-grade biospecimen supply — RUO PBMCs, plasma, serum, and whole blood from its disease-state donor network. GMP cell manufacturing is not a core Sanguine capability.
OrganaBio is designed as a CTDMO (Cell Therapy Development and Manufacturing Organization) with GMP apheresis collection and cell processing infrastructure. The disease-state RUO portfolio is built on the same collection and processing infrastructure used for GMP clinical manufacturing. This integration is what enables the RUO-to-GMP donor continuity model described elsewhere on this site.
For programs that need disease-state PBMCs for research and have no intention of using the same supplier for GMP manufacturing, this distinction doesn’t matter. For programs that are building toward a CTDMO relationship — where the starting material supplier will eventually supply GMP apheresis for clinical manufacturing — OrganaBio’s integrated model avoids the supplier swap and comparability study that would be required when transitioning from Sanguine’s RUO supply to a separate GMP supplier.
Fresh vs. Cryopreserved Access
Sanguine’s disease-state portfolio is predominantly cryopreserved. Fresh disease-state collections can be arranged through Sanguine’s donor network but are subject to donor scheduling and geographic availability of donors willing to undergo apheresis-scale collection.
OrganaBio’s disease-state material is cryopreserved, consistent with the RUO market norm. Fresh disease-state collections are available through OrganaBio’s clinical partnerships for programs with defined fresh collection requirements.
Leukopak vs. PBMC Fraction
Sanguine provides smaller-volume disease-state collections — typically whole blood draws or leukapheresis-scale collections yielding PBMC fractions in the 50–200 million cell range. Leukopak-scale disease-state collections (producing billions of PBMCs) require donors willing to undergo a full apheresis procedure, which limits availability through Sanguine’s consumer-facing donor recruitment model.
OrganaBio’s disease-state portfolio includes both PBMC fractions and full leukopak-scale collections depending on the indication and donor. For manufacturing-scale applications requiring billions of input cells from a disease-state donor, leukopak availability matters — and it depends on having donors enrolled in a clinical-grade apheresis program rather than a community donor network.
Summary Comparison
| Factor | OrganaBio | Sanguine Biosciences |
|---|---|---|
| Disease-state indication count | 24 focused indications | 150+ indications |
| Annotation model | Clinical data collection, structured protocols | Donor self-report, questionnaire-based |
| GMP capability | Full GMP apheresis and processing (CTDMO) | RUO only |
| RUO-to-GMP continuity | Yes — same donor pool, same infrastructure | No (requires GMP supplier transition) |
| KIR genotyping | Available on all donors | Not standard |
| Leukopak-scale disease-state | Available for select indications | Limited |
| Format | Fresh and cryopreserved | Predominantly cryopreserved |
For programs where indication breadth is the primary constraint and GMP integration is not relevant to the current development stage, Sanguine’s 150+ indication portfolio is a genuine advantage. For programs in the core autoimmune/oncology space where annotation depth, GMP infrastructure, and CTDMO integration matter, OrganaBio’s model is built for that use case.
Contact OrganaBio’s scientific team to discuss your specific indication, annotation requirements, and how OrganaBio’s disease-state program addresses your research needs.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
View Disease-State PBMCsTalk to Our TeamFrequently Asked Questions
How does OrganaBio’s disease-state donor pool differ structurally from Sanguine’s longitudinal patient cohort model?
OrganaBio maintains a cross-sectional disease-state donor pool — a characterized set of donors with specific conditions available for repeated or one-time collections, organized by indication and clinical annotation. The emphasis is on characterization at collection: HLA typing, subset data, clinical annotation, and COA documentation for each lot. Sanguine operates a longitudinal enrollment model — patients enroll into observational studies and contribute matched samples over time, enabling tracking of the same individual’s immune profile across disease progression or treatment cycles. Structurally, OrganaBio optimizes for lot-specific characterization and defined clinical parameters at ordering; Sanguine optimizes for longitudinal matching from the same patient over time. The choice depends on whether your research question requires matched samples (Sanguine) or well-characterized single-timepoint samples with defined clinical annotation (OrganaBio).
When should I choose longitudinal matched samples over cross-sectional disease-state material?
Choose longitudinal matched samples when your research question requires tracking changes within the same individual over time — disease progression, response to therapy, biomarker evolution at defined timepoints, or pre-treatment versus post-treatment comparison. Sanguine’s longitudinal enrollment model serves these questions well. Choose cross-sectional disease-state material when you need a defined patient population at a specific clinical state — active disease at a specific severity level, treatment-naive, or on stable biologic therapy — without requiring within-patient tracking. OrganaBio’s pool is appropriate for assay development, drug screening, and studies where patient-level variability is controlled through clinical annotation selection rather than within-patient matching.
Is disease-state PBMC material from OrganaBio available as GMP starting material for autoimmune cell therapy manufacturing?
No. Disease-state donor PBMCs from OrganaBio are for research use only and should not be used as GMP starting material for manufacturing cell therapies intended for human use. Autoimmune cell therapy programs — including CAR-Treg therapies for autoimmune disease or CAR-T programs targeting self-reactive immune cells — use the patient’s own apheresis product as GMP starting material, not a third-party disease-state donor pool. The patient’s own T cells are collected under GMP conditions specifically for that individual’s treatment. OrganaBio’s disease-state material is appropriate for in vitro model development, mechanistic research, and drug screening assays where research-grade donor cells are scientifically valid.
What clinical annotations does OrganaBio provide for disease-state donors compared to what Sanguine offers?
OrganaBio provides disease-state annotation covering: confirmed diagnosis, disease stage or activity score (using validated clinical instruments where available), treatment history and current therapy status, time since last dose, relevant comorbidities, and collection-timepoint clinical parameters. HLA typing (6-digit NGS) is performed on all donors. Sanguine’s annotation typically includes similar diagnosis and treatment data with the addition of longitudinal collection timepoint markers (baseline, on-treatment, post-treatment, relapse) and within-patient sample tracking. For researchers who need clinical annotation depth but do not require longitudinal matching, OrganaBio’s cross-sectional characterization provides equivalent or greater clinical detail at the collection level.
Does OrganaBio’s disease-state pool cover the same indications as Sanguine, and are there gaps?
OrganaBio’s disease-state pool covers 24+ indications across autoimmune, oncology, metabolic, and other categories — including conditions like SLE, rheumatoid arthritis, T1D, ankylosing spondylitis, IBD, AML, NHL, and others. Sanguine’s catalog spans a similarly broad indication set with particular depth in autoimmune and metabolic disease where longitudinal enrollment has been established. Gaps in either pool should be evaluated by direct inquiry — indication-specific availability changes as donor enrollment and qualification fluctuate. For indications outside both companies’ standard pools, custom recruitment and collection is available from OrganaBio through the team contact.
